Nuveen Investment Trust has taken a significant step in maintaining regulatory compliance by filing a certification that confirms its recent amendments to the registration statement align with previous filings. This action is crucial for the company as it underscores its commitment to transparency and adherence to SEC regulations.
The filing, dated October 30, 2026, indicates that the amendments to the Registration Statement on Form N-1A for various funds, including the Nuveen Global Equity Income Fund and the Nuveen Multi Cap Value Fund, do not differ from those that would have been filed under Rule 497(c) of the Securities Act. This certification is a routine yet essential part of the regulatory process for investment firms.
Background
Nuveen Investment Trust, incorporated in Massachusetts, operates as an investment entity. The firm is known for its diverse range of mutual funds and investment strategies. As of the latest filings, the company has been active in submitting various forms, including multiple amendments to its registration statement on October 30, 2026.
What the Filing Says
The filing states, "this letter serves to certify that the most recent amendment to the Registration Statement... does not differ from that which would have been filed pursuant to Rule 497(c) of the Securities Act." This statement confirms the company’s adherence to SEC regulations and ensures that its investors are aware of the compliance status.
Impact
This filing may affect various stakeholders, including investors and regulatory bodies, by providing assurance that Nuveen Investment Trust is operating within the legal framework established by the SEC. It also reflects the company's commitment to maintaining investor trust through transparency in its operations.
What's Next
The filing does not say what happens next.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






